Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Mass-Producing Natural Cancer-Killing Cells for Treatment Options for Patients

By BiotechDaily International staff writers
Posted on 27 Mar 2013
Scientists reported that they are in the process of generating natural cancer-killing cells in the laboratory in a quantity that could soon make them feasible for treating patients.

Even though the production of human natural killer (NK) cells in the lab from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) has become routine, it has been on a limited scale. But a new study’s findings demonstrate how to increase the number of resulting cells while in addition decreasing the amount of work and time involved in generating them. “NK cells show promise for cancer therapy,” said Dan Kaufman, MD, PhD, of the Stem Cell Institute, University of Minnesota (UM; Minneapolis; USA). “They are part of the innate immune system and exhibit potent antitumor activity without the need for donor matching and prior treatment. Moreover, the derivation of NK cells from pluripotent stem cells could provide an unlimited source of lymphocytes for ‘off-the-shelf’ therapy.”

Dr. Kaufman was the lead investigator of the study that included colleagues from UM as well as from the Integrated Center of Cellular Therapy and Regenerative Medicine, St. Anne’s University Hospital Brno (Brno, Czech Republic); and the University of Texas (Houston, USA). The study’s findings were published March 20, 2013, in the journal STEM CELLS Translational Medicine.

“Human NK cells have been used to treat patients with refractory malignancies, but a major hindrance to expanded use has been the inefficiency of production,” said Anthony Atala, MD, editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine (Winston-Salem, NC, USA). “The current study has identified a two-stage culture system to efficiently produce the cells in a manner more suitable to clinical translation than previous methods.”

Related Links:

Stem Cell Institute, University of Minnesota



Channels

Genomics/Proteomics

view channel
Image: Cancer cells, left, were pretreated with a drug that blocks the ERK signal, and right, without the pretreatment. Top cells are untreated, while the bottom ones are stimulated (Photo courtesy of the Weizmann Institute of Science).

Prevention of ERK Nuclear Translocation Blocks Cancer Proliferation in Animal Models

A team of cell biologists has shown that the cancer promoting effects of ERK dysregulation can be blocked by low molecular weight drugs that prevent translocation of this kinase from the cells' cytoplasm... Read more

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.